SEC Form 4 · accession 0001209191-15-061957
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank H Valone M.D.
Officer — Chief Medical Officer
Period of report
Jul 20, 2015
Accepted (ET)
Jul 21, 2015 · 8:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 20, 2015 | M | 1,000 | $2.35 | A | 85,748 | D | |
| Common StockF1,F2 | Jul 20, 2015 | S | 1,000 | $23.7024 | D | 84,748 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.35 | Jul 20, 2015 | M | 1,000 | D | — | Dec 3, 2018 | Common Stock | 1,000 | 55,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices between $23.43 and $24.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Fully vested.